A simplified guide to moving from CSV to CSA using Intended Use → Risk → Assurance → Records approach
FDA’s Computer Software Assurance (CSA) guidance reshapes how life‑sciences organizations validate software used in production and quality environments. Instead of the rigid, document‑heavy, “test everything” approach associated with traditional CSV, CSA enables a risk‑based assurance model focused on patient safety, product quality, and system reliability.
The final FDA CSA guidance (February 2026) emphasizes intended use, risk‑appropriate assurance, flexible testing methods, and right‑sized documentation as the pillars of modern validation.
Unlike CSV, which for years encouraged more documentation than insight, CSA is designed to reduce the documentation burden while increasing actual assurance.
Below is a practical, production‑ready way to implement CSA principles.
1. Start With Intended Use
The Foundation of CSA
The FDA states that software must be validated for its intended use when used in production or the quality management system. CSA approach focuses documented testing based on intended use and each process’s risk. This is a major shift away from treating all software functions equally.
How to apply this:
- Identify exactly what the software does in production/quality (MES step enforcement, LMS training verification, nonconformance routing, etc.).
- Determine which features impact product quality or data integrity.
- Document intended use in a simple, direct format—no lengthy narratives required.
2. Use a Risk‑Based Approach
Replace “Test Everything” With “Test What Matters”
FDA’s final guidance reinforces that assurance effort should match the process risk, not the perceived importance of the software category.
Failures that can compromise safety = high process risk → more rigorous testing.
Failures that cannot compromise safety = not high process risk → lighter testing
Practical considerations:
- A MES reject‑logic function is high risk.
- An LMS “forgot password” function is not.
- A cloud‑based document viewer may be moderate‑to‑low risk depending on how it supports QMS activities.
This simplifies validation planning and removes unnecessary testing from low‑impact features.
3. Apply Assurance Activities
Scripted + Unscripted Testing
The FDA explicitly endorses a wide range of testing methods, including unscripted testing such as exploratory, scenario‑based, and error‑guessing techniques.
This reduces validation time, improves defect discovery, and still satisfies regulatory expectations.
Testing Based on Risk Level:
- High‑risk: Scenario testing, challenge testing, or targeted scripted tests.
- Medium‑risk: Exploratory or functional confirmation.
- Low‑risk: Vendor documentation, system walkthroughs, configuration checks.
This replaces slow, rigid, step‑by‑step test scripts with smarter, more effective assurance.
4. Produce Right‑Sized Records
Replace Document Factories with Targeted Evidence
FDA clarifies that documentation should be appropriate to the risk, not excessive.
The agency explicitly aims to reduce “document factories” and encourages records that simply demonstrate:
- What was tested
- Why it was tested
- What was observed
Recommended minimal evidence:
- Intended use summary
- Risk rationale
- Assurance activity record (exploratory notes or scenario outcomes)
- Approval/sign‑off
This lean approach provides sufficient documented evidence to meet FDA expectations without the burden of an over-processed testing matrix.
5. Operationalize CSA as a Repeatable Program
To make CSA sustainable across MES, QMS, LIMS, EMS, AI and other cloud‑hosted platforms, organizations should build a consistent workflow:
- Define intended use per feature or function
- Category determination based on the end-use process quality and compliance risk
- Select assurance activities (scripted or unscripted)
- Execute and capture results (Targeted est evidence)
- Maintain traceability only to the level needed
- Continuously improve (leverage supplier documentation, automate tests as feasible)
This supports FDA’s shift toward innovation, modern tooling, and flexible software approaches.
6. How CSA Modernizes the Validation Landscape
By “flipping” CSV into CSA, FDA encourages a system that is:
- Risk‑first, not document‑first
- Outcome‑driven, not artifact‑driven
- Transparent, not bureaucratic
- Aligned with modern software delivery models, including cloud, SaaS, and rapid release cycles
Under CSA, organizations no longer waste time prioritizing low risk functional testing.
Instead, they invest validation effort where it protects the patient and ensures true process reliability.
Summary
CSA is a modernization of mindset, not merely CSV guidance.
FDA’s CSA framework breaks validation into four core, actionable steps:
- Intended Use — what features matter?
- Risk Approach — what could go wrong?
- Assurance Activities — what testing makes sense?
- Records — what minimal evidence demonstrates control?
This makes validation faster, transparent, more meaningful, and better aligned with real manufacturing needs.
About PSC Biotech®
Founded in 1996, PSC Biotech® has spent more than two decades providing life sciences with essential services to ensure that healthcare products are developed, manufactured, and distributed to the highest standards in compliance with all applicable regulatory requirements.
Our goal is to skyrocket our clients’ success. To achieve this, our method is straightforward; we put the client’s needs first. We attain top-tier expertise for each project stage, from generating comprehensive project plans to reaching extensive production operations into attentive asset management, authenticity, and non-expendable ventures. Since our inception, PSC Biotech® has served as a strategic partner to emerging and established life science companies, all to help bring their life-saving products to market.
PSC Biotech® operates in 52 countries globally and has served thousands of clients. Employing a global team of skilled professionals and experts that span strategically located offices in North America, Europe, Asia, Australia, and the Middle East, we are proud of the roles we have fulfilled to help our clients achieve success.
Explore PSC Biotech’s full range of services at biotech.com, and follow us on LinkedIn to stay up to date!
https://www.linkedin.com/company/psc-biotech-corp/